Files in this item
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
Item metadata
dc.contributor.author | Kissling, Esther | |
dc.contributor.author | Hooiveld, Mariette | |
dc.contributor.author | Sandonis Martín, Virginia | |
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | William, Naoma | |
dc.contributor.author | Vilcu, Ana Maria | |
dc.contributor.author | Mazagatos, Clara | |
dc.contributor.author | Domegan, Lisa | |
dc.contributor.author | de Lusignan, Simon | |
dc.contributor.author | Meijer, Adam | |
dc.contributor.author | Machado, Ausenda | |
dc.contributor.author | Brytting, Mia | |
dc.contributor.author | Casado, Itziar | |
dc.contributor.author | Murray, Josephine L.K. | |
dc.contributor.author | Belhillil, Sylvie | |
dc.contributor.author | Larrauri, Amparo | |
dc.contributor.author | O'Donnell, Joan | |
dc.contributor.author | Tsang, Ruby | |
dc.contributor.author | de Lange, Marit | |
dc.contributor.author | Rodrigues, Ana Paula | |
dc.contributor.author | Riess, Maximilian | |
dc.contributor.author | Castilla, Jesús | |
dc.contributor.author | Hamilton, Mark | |
dc.contributor.author | Falchi, Alessandra | |
dc.contributor.author | Pozo, Francisco | |
dc.contributor.author | Dunford, Linda | |
dc.contributor.author | Cogdale, Jade | |
dc.contributor.author | Jansen, Tessa | |
dc.contributor.author | Guiomar, Raquel | |
dc.contributor.author | Enkirch, Theresa | |
dc.contributor.author | Burgui, Cristina | |
dc.contributor.author | Sigerson, Debbie | |
dc.contributor.author | Blanchon, Thierry | |
dc.contributor.author | Martínez Ochoa, Eva María | |
dc.contributor.author | Connell, Jeff | |
dc.contributor.author | Ellis, Joanna | |
dc.contributor.author | van Gageldonk-Lafeber, Rianne | |
dc.contributor.author | Kislaya, Irina | |
dc.contributor.author | Rose, Angela MC | |
dc.contributor.author | Valenciano, Marta | |
dc.contributor.author | I-MOVE-COVID-19 primary care study team | |
dc.date.accessioned | 2022-09-23T11:30:14Z | |
dc.date.available | 2022-09-23T11:30:14Z | |
dc.date.issued | 2021-07-22 | |
dc.identifier | 280689252 | |
dc.identifier | 2a8ba9c1-abcd-4a74-9196-0b4dbcf0542c | |
dc.identifier | 85112153857 | |
dc.identifier | 34296676 | |
dc.identifier.citation | Kissling , E , Hooiveld , M , Sandonis Martín , V , Martínez-Baz , I , William , N , Vilcu , A M , Mazagatos , C , Domegan , L , de Lusignan , S , Meijer , A , Machado , A , Brytting , M , Casado , I , Murray , J L K , Belhillil , S , Larrauri , A , O'Donnell , J , Tsang , R , de Lange , M , Rodrigues , A P , Riess , M , Castilla , J , Hamilton , M , Falchi , A , Pozo , F , Dunford , L , Cogdale , J , Jansen , T , Guiomar , R , Enkirch , T , Burgui , C , Sigerson , D , Blanchon , T , Martínez Ochoa , E M , Connell , J , Ellis , J , van Gageldonk-Lafeber , R , Kislaya , I , Rose , A MC , Valenciano , M & I-MOVE-COVID-19 primary care study team 2021 , ' Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 ' , Eurosurveillance , vol. 26 , no. 29 , 2100670 . https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670 | en |
dc.identifier.issn | 1025-496X | |
dc.identifier.other | ORCID: /0000-0002-1511-7944/work/116910274 | |
dc.identifier.uri | https://hdl.handle.net/10023/26062 | |
dc.description | This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. | en |
dc.description.abstract | We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals. | |
dc.format.extent | 7 | |
dc.format.extent | 149080 | |
dc.language.iso | eng | |
dc.relation.ispartof | Eurosurveillance | en |
dc.subject | COVID-19 | en |
dc.subject | Europe | en |
dc.subject | Multicentre study | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Test-negative design | en |
dc.subject | Vaccine effectiveness | en |
dc.subject | QR355 Virology | en |
dc.subject | RA0421 Public health. Hygiene. Preventive Medicine | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | Virology | en |
dc.subject | Epidemiology | en |
dc.subject | Public Health, Environmental and Occupational Health | en |
dc.subject | 3rd-DAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | NIS | en |
dc.subject.lcc | QR355 | en |
dc.subject.lcc | RA0421 | en |
dc.subject.lcc | RM | en |
dc.title | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 | en |
dc.type | Journal article | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Education Division | en |
dc.identifier.doi | 10.2807/1560-7917.ES.2021.26.29.2100670 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.